Sarah D de Ferranti1, Angie Mae Rodday2, Michael M Mendelson2, John B Wong2, Laurel K Leslie2, R Christopher Sheldrick2. 1. From Department of Cardiology, Boston Children's Hospital, MA (S.D.d.F., M.M.M.); Institute for Clinical Research and Health Policy Studies (A.M.R., L.K.L., R.C.S.) and Division of Clinical Decision Making (J.B.W.), Tufts Medical Center, Boston, MA; and Boston University School of Medicine, MA (M.M.M.). Sarah.deferranti@cardio.chboston.org. 2. From Department of Cardiology, Boston Children's Hospital, MA (S.D.d.F., M.M.M.); Institute for Clinical Research and Health Policy Studies (A.M.R., L.K.L., R.C.S.) and Division of Clinical Decision Making (J.B.W.), Tufts Medical Center, Boston, MA; and Boston University School of Medicine, MA (M.M.M.).
Abstract
BACKGROUND: The prevalence of familial hypercholesterolemia (FH) is commonly reported as 1 in 500. European reports suggest a higher prevalence; the US FH prevalence is unknown. METHODS AND RESULTS: The 1999 to 2012 National Health and Nutrition Examination Survey (NHANES) participants ≥20 years of age (n=36 949) were analyzed to estimate the prevalence of FH with available Dutch Lipid Clinic criteria, including low-density lipoprotein cholesterol and personal and family history of premature atherosclerotic cardiovascular disease. Prevalence and confidence intervals of probable/definite FH were calculated for the overall population and by age, sex, obesity status (body mass index ≥30 kg/m(2)), and race/ethnicity. Results were extrapolated to the 210 million US adults ≥20 years of age. The estimated overall US prevalence of probable/definite FH was 0.40% (95% confidence interval, 0.32-0.48) or 1 in 250 (95% confidence interval, 1 in 311 to 209), suggesting that 834 500 US adults have FH. Prevalence varied by age, being least common in 20 to 29 year olds (0.06%, 1 in 1557) and most common in 60 to 69 year olds (0.85%, 1 in 118). FH prevalence was similar in men and women (0.40%, 1 in 250) but varied by race/ethnicity (whites: 0.40%, 1 in 249; blacks: 0.47%, 1 in 211; Mexican Americans: 0.24%, 1 in 414; other races: 0.29%, 1 in 343). More obese participants qualified as probable/definite FH (0.58%, 1 in 172) than nonobese (0.31%, 1 in 325). CONCLUSIONS: FH, defined with Dutch Lipid Clinic criteria available in NHANES, affects 1 in 250 US adults. Variations in prevalence by age and obesity status suggest that clinical criteria may not be sufficient to estimate FH prevalence.
BACKGROUND: The prevalence of familial hypercholesterolemia (FH) is commonly reported as 1 in 500. European reports suggest a higher prevalence; the US FH prevalence is unknown. METHODS AND RESULTS: The 1999 to 2012 National Health and Nutrition Examination Survey (NHANES) participants ≥20 years of age (n=36 949) were analyzed to estimate the prevalence of FH with available Dutch Lipid Clinic criteria, including low-density lipoprotein cholesterol and personal and family history of premature atherosclerotic cardiovascular disease. Prevalence and confidence intervals of probable/definite FH were calculated for the overall population and by age, sex, obesity status (body mass index ≥30 kg/m(2)), and race/ethnicity. Results were extrapolated to the 210 million US adults ≥20 years of age. The estimated overall US prevalence of probable/definite FH was 0.40% (95% confidence interval, 0.32-0.48) or 1 in 250 (95% confidence interval, 1 in 311 to 209), suggesting that 834 500 US adults have FH. Prevalence varied by age, being least common in 20 to 29 year olds (0.06%, 1 in 1557) and most common in 60 to 69 year olds (0.85%, 1 in 118). FH prevalence was similar in men and women (0.40%, 1 in 250) but varied by race/ethnicity (whites: 0.40%, 1 in 249; blacks: 0.47%, 1 in 211; Mexican Americans: 0.24%, 1 in 414; other races: 0.29%, 1 in 343). More obeseparticipants qualified as probable/definite FH (0.58%, 1 in 172) than nonobese (0.31%, 1 in 325). CONCLUSIONS: FH, defined with Dutch Lipid Clinic criteria available in NHANES, affects 1 in 250 US adults. Variations in prevalence by age and obesity status suggest that clinical criteria may not be sufficient to estimate FH prevalence.
Authors: Amanda M Perak; Hongyan Ning; Sarah D de Ferranti; Holly C Gooding; John T Wilkins; Donald M Lloyd-Jones Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Candace L Jackson; James Z Keeton; Stephen J Eason; Zahid A Ahmad; Colby R Ayers; M Odette Gore; Darren K McGuire; Merlyn H Sayers; Amit Khera Journal: JAMA Cardiol Date: 2019-07-01 Impact factor: 14.676
Authors: May E Montasser; Elizabeth A O'Hare; Xiaochun Wang; Alicia D Howard; Rebecca McFarland; James A Perry; Kathleen A Ryan; Kenneth Rice; Cashell E Jaquish; Alan R Shuldiner; Michael Miller; Braxton D Mitchell; Norann A Zaghloul; Yen-Pei C Chang Journal: Circulation Date: 2018-09-25 Impact factor: 29.690
Authors: Roopa Mehta; Rafael Zubirán; Alexandro J Martagón; Alejandra Vazquez-Cárdenas; Yayoi Segura-Kato; María Teresa Tusié-Luna; Carlos A Aguilar-Salinas Journal: J Lipid Res Date: 2016-10-24 Impact factor: 5.922
Authors: Shawn B Bender; Vincent J de Beer; Darla L Tharp; Douglas K Bowles; M Harold Laughlin; Daphne Merkus; Dirk J Duncker Journal: Basic Res Cardiol Date: 2016-09-13 Impact factor: 17.165